Premium
Dyskinesia and wearing‐off following dopamine D 1 agonist treatment in drug‐naive 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned primates
Author(s) -
Blanchet P. J.,
Grondin R.,
Bédard P. J.
Publication year - 1996
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870110117
Subject(s) - dyskinesia , agonist , dopamine , dopamine agonist , medicine , neuroscience , parkinson's disease , pharmacology , psychology , anesthesia , dopaminergic , receptor , disease
The motor effects of the short‐acting, full D 1 agonist SKF 82958 were studied in three drug‐naive, 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned, parkinsonian monkeys treated for 4 weeks. D 1 receptor stimulation with SKF 82958 effectively relieved parkinsonism but induced choreic dyskinesia (n = 2) and a shorter duration of motor benefit (n = 3) over time. Isolated, short‐lived D 1 receptor activation would not appear to confer advantage over levodopa for dyskinesia prevention. Our data also support the involvement of postsynaptic dopamine receptor mechanisms in the wearing‐off phenomenon seen in levodopa‐treated parkinsonian patients.